Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Receives $20.29 Average PT from Analysts

Posted by on May 28th, 2026

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA – Get Free Report) has received a consensus rating of “Moderate Buy” from the eight brokerages that are covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation and seven have given a buy recommendation to the company. The average twelve-month target price among analysts that have covered the stock in the last year is $20.2857.

ENTA has been the subject of a number of research analyst reports. Rodman & Renshaw initiated coverage on shares of Enanta Pharmaceuticals in a research report on Thursday, March 26th. They set a “buy” rating and a $20.00 price objective for the company. Wall Street Zen upgraded shares of Enanta Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Saturday, May 23rd. HC Wainwright reiterated a “buy” rating and set a $20.00 price objective on shares of Enanta Pharmaceuticals in a research report on Tuesday, February 10th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Enanta Pharmaceuticals in a research report on Monday, April 20th.

Check Out Our Latest Stock Report on Enanta Pharmaceuticals

Hedge Funds Weigh In On Enanta Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in ENTA. Janus Henderson Group PLC increased its position in Enanta Pharmaceuticals by 91.6% during the 4th quarter. Janus Henderson Group PLC now owns 3,729,659 shares of the biotechnology company’s stock worth $58,761,000 after purchasing an additional 1,782,745 shares in the last quarter. Commodore Capital LP acquired a new position in Enanta Pharmaceuticals in the 3rd quarter valued at approximately $9,576,000. Krensavage Asset Management LLC increased its position in Enanta Pharmaceuticals by 30.8% in the 4th quarter. Krensavage Asset Management LLC now owns 2,766,390 shares of the biotechnology company’s stock valued at $43,626,000 after acquiring an additional 651,946 shares during the period. Farallon Capital Management LLC increased its position in Enanta Pharmaceuticals by 30.6% in the 4th quarter. Farallon Capital Management LLC now owns 2,772,262 shares of the biotechnology company’s stock valued at $43,719,000 after acquiring an additional 650,000 shares during the period. Finally, Spruce Street Capital LP increased its position in Enanta Pharmaceuticals by 139.3% in the 1st quarter. Spruce Street Capital LP now owns 932,598 shares of the biotechnology company’s stock valued at $11,779,000 after acquiring an additional 542,911 shares during the period. 94.99% of the stock is currently owned by institutional investors and hedge funds.

Enanta Pharmaceuticals Trading Down 2.5%

Shares of Enanta Pharmaceuticals stock opened at $13.19 on Friday. The company has a 50 day moving average of $13.60 and a 200-day moving average of $13.74. Enanta Pharmaceuticals has a 1-year low of $5.78 and a 1-year high of $17.15. The company has a market cap of $383.57 million, a PE ratio of -5.09 and a beta of 1.01.

Enanta Pharmaceuticals (NASDAQ:ENTA – Get Free Report) last issued its quarterly earnings results on Monday, May 11th. The biotechnology company reported ($0.45) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.46) by $0.01. The company had revenue of $17.16 million during the quarter, compared to the consensus estimate of $17.03 million. Enanta Pharmaceuticals had a negative net margin of 89.56% and a negative return on equity of 64.04%. Research analysts forecast that Enanta Pharmaceuticals will post -2.01 earnings per share for the current year.

Enanta Pharmaceuticals Company Profile

(Get Free Report)

Enanta Pharmaceuticals, Inc is a biotechnology company headquartered in Watertown, Massachusetts, specializing in the discovery and development of novel, small-molecule drugs targeting viral diseases. Leveraging a proprietary chemistry platform, Enanta has built extensive expertise in designing potent inhibitors of viral proteases and polymerases. The company initially gained recognition through partnerships focused on hepatitis C virus (HCV), where its protease inhibitors formed a key component of ABBVIE’s direct‐acting antiviral regimens.

Building on its HCV experience, Enanta has expanded its pipeline to address respiratory syncytial virus (RSV) and other viral infections.

Featured Stories

Analyst Recommendations for Enanta Pharmaceuticals (NASDAQ:ENTA)

Receive News & Ratings for Enanta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.